達勁生技股份有限公司
Update：2026/11/10
Industries
Main Industry
Health Care
Main Product/Service
1. "RaptDx" Disposable Chip-Based Quantitative PCR Device: Specially designed for rapid on-site testing, enabling molecular amplification and precise quantification of key biomarkers.
2. "EZDx" Non-Invasive cfDNA Liquid Biopsy System Device: Provides blood and saliva testing for tumor profiling to predict applicable targeted therapies.
2. "EZDx" Non-Invasive cfDNA Liquid Biopsy System Device: Provides blood and saliva testing for tumor profiling to predict applicable targeted therapies.
The content above was translated by Ai
Founded Year
2023
Unified Business No.
28115334
Status
Active
Number of Employees
0
Total Paid-in
Capital
3,200,000 (NT$)
Location of Company
Taiwan
, Hsinchu County
Website
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups.
Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed.
Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Professor Dar-Bin Shieh of National Cheng Kung University is the founder of 達勁公司. The company develops a portable, rapid, and precise molecular Point of Care Testing (POCT) system, targeting primary care clinics, care institutions, and other facilities as its target market. This system enables early control of epidemics during pandemic periods, provides precision medicine to elderly high-risk groups to reduce severe illness, and utilizes POCT to reduce referrals for centralized testing, thereby relieving the burden on acute and critical care medical resources. The startup plans to research and develop solutions for respiratory diseases, mycoplasma pneumonia, gastrointestinal infections, sexually transmitted diseases, antimicrobial resistance monitoring, and oncology precision medicine to seize market growth opportunities. Its core technologies consist of magnetic nanoparticle capture, optoelectronic integrated chips, room-temperature reagents, and molecular diagnostic devices with mobile heating mechanisms.
The content above was translated by Ai
